Can the "right" EGFR-specific mAb dramatically improve EGFR-targeted therapy?

EGF receptor (EGFR)-specific monoclonal antibodies (mAb) display limited therapeutic efficacy in EGFR-positive solid tumors. To overcome this limitation, the significant improvement of the antibodydependent cell-mediated cytotoxicity-mediated antitumor activity of a novel EGFR-specific mAb is described. Its potential impact on the efficacy of immunotherapy for EGFR-positive solid tumors is discussed. © 2012 American Association for Cancer Research